Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01992341 · ClinicalTrials.gov registry record · Phase 1

AMG 386 Drug-Drug Interaction Study With Paclitaxel

A Phase 1 study of Advanced Solid Tumors, sponsored by Amgen.

Completed
Registry status
Phase 1
Development phase
35
Enrollment target
2
Study locations

NCT01992341 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Amgen. The registered enrollment target is 35 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01992341, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 1
Development phase
35 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG Paclitaxel
  • DRUG AMG 386

Study Locations (2)

Colorado

  • University of Colorado Cancer Center - Aurora

Utah

  • University of Utah Huntsman Cancer Institute - Salt Lake City

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2012-07
Est. Completion 2014-09
Phase Phase 1

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01992341

The ClinicalTrials.gov registry entry for NCT01992341 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (82% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.

NCT01992341 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, Utah.

Frequently Asked Questions

What is clinical trial NCT01992341 about?

NCT01992341 is a clinical study titled "AMG 386 Drug-Drug Interaction Study With Paclitaxel". The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel

What is the current status of trial NCT01992341?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2012-07. Estimated completion is 2014-09.

What conditions does trial NCT01992341 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT01992341?

The interventions under investigation include: Paclitaxel (DRUG), AMG 386 (DRUG).

Who is sponsoring clinical trial NCT01992341?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01992341 being conducted?

This trial has 2 study locations across Colorado, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.